Expanding the repertoire of immunomodulatory drugs: targeting the melanocortin system using engineered cyclic peptides

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1120066

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Autoimmune diseases, including rheumatoid arthritis and psoriasis, have profound impacts on the lives of many Australians. New drugs are required for these diseases as existing treatments are expensive, become less effective with repeated use or cause adverse side effects. My project will work towards addressing this need by investigating the potential of ultrastable cyclic miniproteins as scaffolds for displaying bioactive peptides that are known to restore immune self-tolerance.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $318,768.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Proteins and Peptides

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

G-protein coupled receptors | drug design | peptides | psoriasis | rheumatoid arthritis

Related Links